BIO Asia-Taiwan 2023 attracts 100,000 visitors from 31 countries
BioSpectrum Asia|BioSpectrum Asia Sep 2023
The Taiwan Bio Industry Organization (Taiwan BIO) and the global Biotechnology Innovation Organisation (BIO) ignited Taiwan’s three-day conference BIO Asia-Taiwan 2023 from July 26 to 30 at the Taipei Nangang International Exhibition Center (TaiNEX 1 and TaiNEX 2).
Hithaishi C Bhaskar
BIO Asia-Taiwan 2023 attracts 100,000 visitors from 31 countries

The Onsite + Online International Conference and Exhibition was launched with the theme “Embracing Asian Dynamics” to comprehensively address the opportunities and challenges in Asia’s biomedical and healthcare sectors. Enthralling conferences, exhibitions, and collaboration forums substantiated innovations, exemplified trends and business partnership opportunities.

Johnsee Lee, Chairman of BIO Asia-Taiwan unveiled the theme of BIO Asia-Taiwan 2023 “Embracing Asian Dynamics” primarily focusing on ‘Innovation, market supply and investment’’ around precision health and biopharma Contract Development and Manufacturing Organization (CDMO) operations”. Major highlights spanned over:

Innovation: Innovative platform & tools; New therapeutic modalities; Cell therapy & regenerative medicine; Precision medicine & health; AI and digital health

Market and Supply chain: Biologics & biosimilars Active Pharmaceutical Ingredients (API); CDMO/CMO; Contract Research Organisations (CRO); Public health driven regional collaboration

Investment: Opportunities amid challenges; Early stage financing; Cross border investment; Capital markets & IPO; Merger & acquisition; Bio investment with IT funds; Incubation & acceleration

The forum strives to create a platform, build collaboration, and expand international participation and synergy within the Asian biomedical industry. Furthermore, the forum addressed policy and regulation issues in agribusiness and food-biotech sectors, aside from biopharma and healthcare sessions.

Diese Geschichte stammt aus der BioSpectrum Asia Sep 2023-Ausgabe von BioSpectrum Asia.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

Diese Geschichte stammt aus der BioSpectrum Asia Sep 2023-Ausgabe von BioSpectrum Asia.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

WEITERE ARTIKEL AUS BIOSPECTRUM ASIAAlle anzeigen
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
BioSpectrum Asia

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
BioSpectrum Asia

Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers

Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
BioSpectrum Asia

Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine

Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
BioSpectrum Asia

Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis

US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singapore designs novel gene therapy offering hope for epilepsy patients
BioSpectrum Asia

Singapore designs novel gene therapy offering hope for epilepsy patients

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Spider venom heart drug moves to clinical trials in Australia
BioSpectrum Asia

Spider venom heart drug moves to clinical trials in Australia

A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).

time-read
1 min  |
BioSpectrum Asia Nov 2024
India develops portable ultrasound scanner for sports injury diagnosis
BioSpectrum Asia

India develops portable ultrasound scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Integris appoints medtech veteran Probir Das as new CEO
BioSpectrum Asia

Integris appoints medtech veteran Probir Das as new CEO

Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Clarity Pharma promotes Michelle Parker to CEO
BioSpectrum Asia

Clarity Pharma promotes Michelle Parker to CEO

Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
BioSpectrum Asia

Dr Makoto Sugita steps in as President of Nxera Pharma Japan

Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.

time-read
1 min  |
BioSpectrum Asia Nov 2024